Century Therapeutics, Inc.
IPSC
Rank in Stocks
#14380
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering... Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Share Price
$1.81
Last synced: 2026-11-09
Market Cap
$327.75M
Change (1 day)
7.74%
Change (1 year)
221.32%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Century Therapeutics, Inc. (IPSC)
Category
Healthcare
Earnings for Century Therapeutics, Inc. (IPSC)
Earnings in Jun 2026 TTM: $-109.86M
According to Century Therapeutics, Inc.'s latest financial reports, its current earnings (TTM) are $-109.86M. In 2025 the company earned $-9.65M, an increase over its 2024 earnings of $-124.78M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Century Therapeutics, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-109.86M | 1,038.64% |
| 2025 | $-9.65M | -92.27% |
| 2024 | $-124.78M | -7.43% |
| 2023 | $-134.79M | 3.02% |
| 2022 | $-130.84M | 36.60% |
| 2021 | $-95.78M | 78.78% |
| 2020 | $-53.58M | -78.11% |
| 2019 | $-244.77M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -4,432.49% |
US
|
|
| $-2.73B | 2,384.16% |
US
|
|
| $-4.02B | 3,555.87% |
AU
|
|
| $2.83B | -2,672.30% |
BE
|
|
| $1.50B | -1,462.64% |
NL
|
Questions about Century Therapeutics, Inc.'s net income
What is Century Therapeutics, Inc.'s net income?
Century Therapeutics, Inc.'s net income over the last twelve months is $-109.86M, as of Jun 2026.
What was Century Therapeutics, Inc.'s net income in 2025?
In 2025, Century Therapeutics, Inc.'s net income was $-9.65M, compared with $-124.78M in 2024.
How has Century Therapeutics, Inc.'s net income changed since 2020?
From 2020 to 2025, Century Therapeutics, Inc.'s net income was highest in 2025 ($-9.65M) and lowest in 2023 ($-134.79M).
How does Century Therapeutics, Inc.'s net income compare with similar companies?
Century Therapeutics, Inc.'s net income ($-109.86M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.